INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,393,977 | -17.7% | 65,156 | 0.0% | 0.73% | -15.1% |
| Q2 2023 | $4,125,678 | +16.3% | 65,156 | -0.5% | 0.86% | +7.6% |
| Q1 2023 | $3,546,067 | +3.4% | 65,486 | +1.0% | 0.80% | -0.6% |
| Q4 2022 | $3,430,063 | +13.7% | 64,816 | -0.1% | 0.80% | +4.7% |
| Q3 2022 | $3,018,000 | -18.5% | 64,853 | -0.0% | 0.77% | -13.6% |
| Q2 2022 | $3,702,000 | -6.7% | 64,858 | 0.0% | 0.89% | +10.1% |
| Q1 2022 | $3,969,000 | – | 64,858 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |